Abstract:The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.

Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis

Ferroptosis and Renal Fibrosis: A New Target for the Future (Review)

Ferroptosis as an emerging therapeutic target in liver diseases

Recent progress in the effect of ferroptosis of HSCs on the development of liver fibrosis

The role of ferroptosis-related non-coding RNA in liver fibrosis

Ferroptosis as a new therapeutic opportunity for nonviral liver disease.

Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications

Ferroptosis: A New Strategy for the Treatment of Fibrotic Diseases

Ferroptosis in Pulmonary Fibrosis: an Emerging Therapeutic Target

Targeting ferroptosis with natural products in liver injury: new insights from molecular mechanisms to targeted therapies

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

The Emerging Role of Ferroptosis in Liver Diseases

Ferroptosis in organ fibrosis: From mechanisms to therapeutic medicines

Novel Therapeutic Targets in Liver Fibrosis

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Research mechanisms of and pharmaceutical treatments for ferroptosis in liver diseases

The Emerging Roles of Ferroptosis in Organ Fibrosis and Its Potential Therapeutic Effect.

Role of Ferroptosis in Non-Alcoholic Fatty Liver Disease and Its Implications for Therapeutic Strategies

The Progression for the Therapy of Liver Fibrosis Targeting to Hepatic Stellate Cells

Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications